

\$ IFW
CASE HA719f DIV 2

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Henry H. Gu
Type or print name


Signature

July 14, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF MURUGESAN ET AL.

APPLICATION NO: 10/672,572

FILED: SEPTEMBER 26, 2003

FOR: BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN
RECEPTOR ANTAGONISTS

Mail Stop **Box Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

07/16/2004 KBETENA1 00000053 193880 10672572
01 FC:1806 180.00 DA

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-6457
Date: July 14, 2004


Henry H. Gu
Agent for Applicants
Reg. No. 55,227



CASE HA719f DIV 2

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Henry H. Gu
Type or print name


Signature

July 14, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF MURUGESAN ET AL.

APPLICATION NO: 10/672,572

FILED: SEPTEMBER 26, 2003

FOR: BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN
RECEPTOR ANTAGONISTS

Mail Stop Box Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-6457
Date: July 14, 2004


Henry H. Gu
Agent for Applicants
Reg. No. 55,227


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
HA719f DIV 2
APPLICATION NO.
10/672,572
APPLICANT
MURUGESAN ET AL.
FILING DATE
SEPTEMBER 26, 2003

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AE							
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AK	Bohlender et al., "Synergistic Effects of AT ₁ and ET _A Receptor Blockade in a Transgenic, Angiotension II-Dependent, Rat Model", Hypertension, Vol. 35(4), pp. 992-997 (2000)
	AL	Chua et al., "Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells", Biochimica et Biophysica Acta, Vol. 1178, pp. 201-206 (1993)
	AM	Dhein et al., "Long-Term Effects of the Endothelin _A Receptor Antagonist LU 135252 and the Angiotensin-Converting Enzyme Inhibitor Trandolapril on Diabetic Angiopathy and Nephropathy in a Chronic Type I Diabetes Mellitus Rat Model", J. of Pharmacology and Experimental Therapeutics, Vol. 293(2), pp. 351-359 (2000)
	AN	Ferrario, C.M., "The Renin-Angiotensin System: Importance in Physiology and Pathology", J. Cardiovasc. Pharmacol., Vol. 15(Suppl. 3), pp. S1-S5, (1990)
	AO	Gardiner et al., "Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats", British J. of Pharmacology, Vol. 116, pp. 2237-2244 (1995)
	AP	Ikeda et al., "Antihypertensive Effects of a Mixed Endothelin-A- and -B- Receptor Antagonist, J-104132, Were Augmented in the Presence of an ATI-Receptor Antagonist, MK-954", J. of Cardiovascular Pharmacology, Vol. 36(Suppl. 1), pp. S337-S341 (2000)
	AQ	Imai et al., "Induction of Endothelin-1 Gene by Angiotensin and Vasopressin in Endothelial Cells", Hypertension, Vol. 19, pp. 753-757 (1992)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
HA719f DIV 2
APPLICATION NO.
10/672,572
APPLICANT
MURUGESAN ET AL.
FILING DATE
SEPTEMBER 26, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Inoue et al., "The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 2863-2867, April 1989
AS	Massart et al., "Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension", J. Hypertension, Vol. 16, pp. 835-841 (1998)
AT	Yanagisawa et al., "A novel potent vasoconstrictor peptide produced by vascular endothelial cells", Nature, Vol. 332, pp. 411-415 (31 March 1988)
AU	
AV	
AW	
AX	
AY	
AZ	
BA	
BB	
BC	
BD	
BE	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.